Uni-Bio Science Group

Uni-Bio Science Group ROCE

The Return on Capital Employed (ROCE) of Uni-Bio Science Group (690.HK) as of Oct 22, 2026 is 27.46 %. In the previous year, Return on Capital Employed (ROCE) was 29.53 % — a change of -7.00% (lower).

ROCE

27.46 %

YoY

-7.00%

Last updated:

In 2024, Uni-Bio Science Group's return on capital employed (ROCE) was 27.46 %, a -7.00% increase from the 29.53 % ROCE in the previous year.

The Uni-Bio Science Group ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2017
-23.26 HKD
Jan 1, 2018
-58.81 HKD
Jan 1, 2019
-24.49 HKD
Jan 1, 2020
-20.52 HKD
Jan 1, 2021
-1.21 HKD
Jan 1, 2022
23.21 HKD
Jan 1, 2023
29.53 HKD
Jan 1, 2024
27.46 HKD
The Uni-Bio Science Group ROCE history
YEARROCEYoY
27.46 %-7.00%
29.53 %+27.20%
23.21 %-2,013.20%
-1.21 %-94.09%
-20.52 %-16.21%
-24.49 %-58.36%
-58.81 %+152.84%
-23.26 %+86.32%
-12.48 %+9.59%
-11.39 %+41.30%
-8.06 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Uni-Bio Science Group Stock analysis

What does Uni-Bio Science Group do? Uni-Bio Science Group Ltd. generates revenue through four segments: in-house chemical pharmaceutical products like Pinapu, in-house biological pharmaceutical products such as GeneTime and GeneSoft, in-house biological pipeline products including Uni-E4 and Uni-PTH, and third-party pharmaceutical products. The company manufactures and sells its own chemical and biological products while also distributing third-party pharmaceuticals. Its primary customers are healthcare providers and pharmaceutical distributors purchasing these branded products. The firm's revenue streams are directly tied to the production and distribution of these specific branded pharmaceuticals across its operational segments. The in-house chemical pharmaceutical segment focuses on products like Pinapu, which is sold to medical institutions and pharmacies. The biological pharmaceutical segment markets GeneTime and GeneSoft for specialized treatments, targeting hospitals and clinics. The biological pipeline segment develops Uni-E4 and Uni-PTH for future commercialization, while third-party pharmaceutical sales involve distributing external brands without direct manufacturing. These segments collectively drive the company's revenue through product sales and distribution agreements. Uni-Bio Science Group's business model relies on both direct manufacturing of its branded pharmaceuticals and third-party product distribution. The company's revenue comes from the sale of Pinapu, GeneTime, GeneSoft, Uni-E4, and Uni-PTH as well as third-party pharmaceuticals. Healthcare institutions and pharmaceutical distributors are the key buyers of these products across all segments, with the in-house products forming the core of the company's revenue generation strategy. Uni-Bio Science Group is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Uni-Bio Science Group's Return on Capital Employed (ROCE)

Uni-Bio Science Group's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Uni-Bio Science Group's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Uni-Bio Science Group's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Uni-Bio Science Group’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Uni-Bio Science Group stock

Return on Capital Employed (ROCE) of Uni-Bio Science Group is 27.46 % in 2024.

Return on Capital Employed (ROCE) of Uni-Bio Science Group changed from 29.53 % to 27.46 %, representing a -7.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Uni-Bio Science Group since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Uni-Bio Science Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Uni-Bio Science Group

All Key Metrics — Uni-Bio Science Group